These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 12649305

  • 1. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL, Rizzo CA, West RE, Aslanian R, McCormick K, Bryant M, Hsieh Y, Korfmacher W, Mingo GG, Varty L, Williams SM, Shih NY, Egan RW, Hey JA.
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [Abstract] [Full Text] [Related]

  • 2. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
    Hey JA, Aslanian R, Bolser DC, Chapman RW, Egan RW, Rizzo CA, Shih NY, Fernandez X, McLeod RL, West R, Kreutner W.
    Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
    [Abstract] [Full Text] [Related]

  • 3. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
    McLeod RL, Aslanian R, del Prado M, Duffy R, Egan RW, Kreutner W, McQuade R, Hey JA.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.
    Biochem Pharmacol; 2004 Sep 01; 68(5):933-45. PubMed ID: 15294456
    [Abstract] [Full Text] [Related]

  • 5. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J.
    J Pharmacol Exp Ther; 1998 Nov 01; 287(2):658-66. PubMed ID: 9808693
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of histamine H3 receptors in human saphenous vein and guinea pig ileum.
    Valentine AF, Rizzo CA, Rivelli MA, Hey JA.
    Eur J Pharmacol; 1999 Jan 29; 366(1):73-8. PubMed ID: 10064154
    [Abstract] [Full Text] [Related]

  • 7. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A, Kiec-Kononowicz K, Stark H, Motyl M, Reidemeister S, Ganellin CR, Ligneau X, Schwartz JC, Schunack W.
    J Med Chem; 1999 Feb 25; 42(4):593-600. PubMed ID: 10052966
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
    Mezzomo K, Cumming P, Minuzzi L.
    Eur J Pharmacol; 2007 Jun 14; 564(1-3):75-9. PubMed ID: 17350614
    [Abstract] [Full Text] [Related]

  • 9. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M, Bordi F, Silva C, Rivara S, Crivori P, Plazzi PV, Ballabeni V, Caretta A, Barocelli E, Impicciatore M, Carrupt PA, Testa B.
    J Med Chem; 1997 Aug 01; 40(16):2571-8. PubMed ID: 9258364
    [Abstract] [Full Text] [Related]

  • 10. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B, Elz S, Pertz HH, Stark H, Schunack W.
    Inflamm Res; 2004 Aug 01; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [Abstract] [Full Text] [Related]

  • 11. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA.
    J Pharmacol Exp Ther; 2003 Jun 01; 305(3):887-96. PubMed ID: 12606603
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT, Christiaans JA, Kotisaari S, Laitinen JT, Männistö PT, Tuomisto L, Gynther J.
    J Med Chem; 1999 Apr 08; 42(7):1193-202. PubMed ID: 10197963
    [Abstract] [Full Text] [Related]

  • 13. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
    Reidemeister S, Stark H, Ligneau X, Ganellin CR, Schwartz JC, Schunack W.
    Pharmazie; 2000 Feb 08; 55(2):83-6. PubMed ID: 10723763
    [Abstract] [Full Text] [Related]

  • 14. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
    Krause M, Ligneau X, Stark H, Garbarg M, Schwartz JC, Schunack W.
    J Med Chem; 1998 Oct 08; 41(21):4171-6. PubMed ID: 9767653
    [Abstract] [Full Text] [Related]

  • 15. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
    Garbarg M, Arrang JM, Rouleau A, Ligneau X, Tuong MD, Schwartz JC, Ganellin CR.
    J Pharmacol Exp Ther; 1992 Oct 08; 263(1):304-10. PubMed ID: 1383495
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
    Leurs R, Tulp MT, Menge WM, Adolfs MJ, Zuiderveld OP, Timmerman H.
    Br J Pharmacol; 1995 Oct 08; 116(4):2315-21. PubMed ID: 8564266
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.
    J Pharmacol Exp Ther; 2005 Apr 08; 313(1):165-75. PubMed ID: 15608078
    [Abstract] [Full Text] [Related]

  • 18. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
    Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):117-23. PubMed ID: 17350613
    [Abstract] [Full Text] [Related]

  • 19. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H, Hüls A, Ligneau X, Arrang JM, Schwartz JC, Schunack W.
    Pharmazie; 1997 Jul 01; 52(7):495-500. PubMed ID: 9266588
    [Abstract] [Full Text] [Related]

  • 20. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, Hancock AA.
    J Pharmacol Exp Ther; 2005 Jul 01; 314(1):271-81. PubMed ID: 15821027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.